Mizuho upgraded uniQure (QURE) to Outperform from Neutral with a price target of $30, up from $20. The firm believes the company’s AMT-130 could be a dominant player in the evolving Huntington’s disease landscape. After speaking to key opinion leaders, Mizuho estimates 2035 peak sales of $2.5B. Although the potential for fatal acute liver failure has become a major concerns with AAV-based gene therapy products, AMT-130 is not subjected to this risk given its direct administration into the brain, adds Mizuho.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Promising Outlook for uniQure’s AMT-130 in Huntington’s Disease with Strategic Advancements and Regulatory Alignment
- uniQure N.V. Earnings Call: Progress Amid Challenges
- Biotech stocks rise following Prasad exit from FDA
- uniQure’s Promising Gene Therapy Advances and Strong Financial Position Justify Buy Rating
- uniQure price target lowered to $47 from $58 at Cantor Fitzgerald